Janux Therapeutics Stock (NASDAQ:JANX)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$53.99

52W Range

$5.65 - $65.60

50D Avg

$47.86

200D Avg

$40.48

Market Cap

$2.84B

Avg Vol (3M)

$586.80K

Beta

3.54

Div Yield

-

JANX Company Profile


Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

69

IPO Date

Jun 11, 2021

Website

JANX Performance


JANX Financial Summary


Dec 23Dec 22Dec 21
Revenue$8.08M$8.61M$3.64M
Operating Income$-72.98M$-67.09M$-32.93M
Net Income$-58.29M$-54.15M$-32.56M
EBITDA$-72.98M$-67.09M$-32.93M
Basic EPS-$-1.31$-1.38
Diluted EPS-$-1.31$-1.38

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
CYTCyteir Therapeutics, Inc.
MLYSMineralys Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
FENCFennec Pharmaceuticals Inc.
CSBRChampions Oncology, Inc.
ANTXAN2 Therapeutics, Inc.
KROSKeros Therapeutics, Inc.
HRMYHarmony Biosciences Holdings, Inc.
MNOVMediciNova, Inc.
RZLTRezolute, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ADAGAdagene Inc.
MOLNMolecular Partners AG
ELYMEliem Therapeutics, Inc.